Does b3 decrease skin cancer
Pro Research Analysisby 
Searched over 200M research papers
The Role of Nicotinamide (Vitamin B3) in Decreasing Skin Cancer
Introduction to Nicotinamide and Skin Cancer
Nicotinamide, also known as vitamin B3, has garnered significant attention for its potential role in reducing the incidence of nonmelanoma skin cancers (NMSC), such as basal-cell carcinoma (BCC) and squamous-cell carcinoma (SCC). These types of skin cancers are primarily caused by ultraviolet (UV) radiation exposure. Recent studies have explored the chemopreventive properties of nicotinamide, particularly its ability to enhance DNA repair and reduce UV-induced immunosuppression.
Efficacy of Nicotinamide in Reducing Nonmelanoma Skin Cancers
Phase 3 Randomized Trials
A pivotal phase 3 randomized, double-blind, controlled trial involving 386 participants demonstrated that oral nicotinamide significantly reduced the rate of new nonmelanoma skin cancers by 23% over a 12-month period compared to a placebo group 12. This study highlighted that nicotinamide was particularly effective in reducing the incidence of new SCCs by 30% and BCCs by 20% 12. Additionally, the number of actinic keratoses, which are precursors to skin cancer, was also significantly lower in the nicotinamide group at various intervals throughout the study 12.
Mechanisms of Action
Nicotinamide's protective effects are attributed to its ability to enhance DNA repair mechanisms, reduce UV-induced immunosuppression, and modulate inflammatory responses 46. It also helps restore cellular energy levels post-UV exposure, which is crucial for maintaining skin health and preventing carcinogenesis 46.
Safety and Practicality of Nicotinamide
Safety Profile
The studies consistently reported that nicotinamide is safe and well-tolerated, with no significant differences in adverse events between the nicotinamide and placebo groups 129. This makes it a viable option for long-term use in high-risk populations.
Cost-Effectiveness
Nicotinamide is an inexpensive and widely available supplement, costing approximately $10 per month. This affordability, combined with its efficacy, makes it a practical option for skin cancer prevention in high-risk individuals .
Limitations and Considerations
Specific Populations
While nicotinamide has shown promise in reducing skin cancer rates in immunocompetent individuals, its efficacy in immunosuppressed populations, such as organ-transplant recipients, remains unclear. A study involving transplant recipients did not find a significant reduction in new keratinocyte cancers with nicotinamide treatment . Therefore, further research is needed to determine its effectiveness in these specific groups.
Continuous Use
The benefits of nicotinamide appear to be contingent on continuous use. Discontinuation of the supplement resulted in the loss of its protective effects, emphasizing the need for ongoing treatment to maintain its chemopreventive benefits 19.
Conclusion
Nicotinamide (vitamin B3) has demonstrated significant potential in reducing the incidence of nonmelanoma skin cancers and actinic keratoses in high-risk individuals. Its ability to enhance DNA repair, reduce UV-induced immunosuppression, and maintain cellular energy levels makes it a valuable tool in skin cancer chemoprevention. Given its safety, affordability, and efficacy, nicotinamide represents a promising addition to current skin cancer prevention strategies, particularly for those with a history of skin cancer. However, continuous use is essential to sustain its protective effects, and further research is needed to confirm its benefits in immunosuppressed populations.
Sources and full results
Most relevant research papers on this topic
A Phase 3 Randomized Trial of Nicotinamide for Skin-Cancer Chemoprevention.
Oral nicotinamide is safe and effective in reducing the rates of new nonmelanoma skin cancers and actinic keratoses in high-risk patients.
Oral nicotinamide reduces actinic keratoses in phase II double-blinded randomized controlled trials.
Oral nicotinamide at 500 mg twice daily reduced actinic keratoses in sun-damaged individuals, suggesting its potential as a safe and effective treatment for sun-damaged skin.
Vitamin B Derivative (Nicotinamide)Appears to Reduce Skin Cancer Risk.
Nicotinamide, a vitamin B derivative, may reduce skin cancer risk by enhancing DNA repair and preventing UV-induced immunosuppression.
Oral nicotinamide to reduce actinic cancer: A phase 3 double-blind randomized controlled trial.
Oral nicotinamide 500mg bd significantly reduced the number of new non-melanoma skin cancers compared to placebo in a phase 3 double-blind randomized controlled trial.
Correlation of changes in HIF-1α and p53 expressions with vitamin B3 deficiency in skin cancer patients.
Vitamin B3 supplementation may have a protective effect on skin cancer patients by reducing HIF-1 and p53 expression levels in their tissues.
DOI